Share this:
Could blocking a testosterone receptor lead to a new way of treating an aggressive form of breast cancer? Researchers at Mayo Clinic in Arizona and The Translational Genomics Research Institute (TGen) are exploring this very question.
Preliminary results of the Mayo Clinic-TGen collaborative study show that the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).
TNBC is highly aggressive and affects approximately 10 to 20 percent of breast cancer patients. The disease is characterized by larger, faster-growing tumors than other types of breast cancer and has limited treatment options.
Surgical oncologist and lead researcher Barbara Pockaj, M.D., is presenting these results today at the 65th annual Society of Surgical Oncology conference in Orlando, Fla.
Click here for entire news release.
Soundbites from lead researcher, Barbara Pockaj, M.D., are available in the downloads above.
Expert title: Barbara Pockaj, M.D., Mayo Clinic Surgical Oncologist
Share this:
Related articles
When Joanina Gicobi began her Ph.D. degree five years ago at Mayo Clinic Graduate School of Biomedical Sciences, she was interested in thinking creatively about ways ...
World AIDS Day, observed on Dec. 1, raises awareness about HIV/AIDS and pays tribute to those affected by the disease. Globally, about 39 million people are living ...
Lung cancer is the largest cancer killer of adult men and women worldwide. One of the reasons is that by the time symptoms develop, the ...